243 results about "Mucoproteins" patented technology

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention provides an antibody specifically combined with CDH6 (cadherin 6) and application thereof, and particularly discloses mouse and humanized antibodies combined with CDH6 as well as a preparation method and application thereof, and the mouse and humanized antibodies have better affinity with CDH6 protein and better endocytosis activity, so that the mouse and humanized antibodies can be applied to preparation of medicines for treating tumors and the like.

The invention discloses a polyphenol-based tissue adhesive for promoting wound healing and a preparation method thereof, and relates to the technical field of medical tissue adhesives. The preparation method of the tissue adhesive comprises the following steps: step 1, preparing a polyphenol compound and recombinant mussel mucin into a solution, and uniformly stirring for later use, namely a solution A; 2, preparing a temperature response type high polymer material into a solution for later use, namely a solution B; and 3, mixing the solution A prepared in the step 1 and the solution B prepared in the step 2, fully and uniformly mixing, shaking and centrifuging, and discarding the supernatant. By selecting the temperature response type high polymer material, the tissue adhesive is endowed with the characteristic of temperature sensitivity, so that the modulus of the adhesive at the human body temperature is improved, and the colloid contraction can further promote wound closure. The mussel mucin is introduced to stimulate collagen regeneration of the wound part, activate the immune mechanism and remodel the wound microenvironment so as to achieve the purpose of promoting healing.

The invention relates to mussel mucin-hyaluronic acid nanogel and a preparation method and application thereof and a pharmaceutical composition, and belongs to the field of biomedical materials, the structural formula of the mussel mucin-hyaluronic acid nanogel is # imgabs0 #, Mussel mucin is a mussel mucin molecule, and n is the number of repetitive units. The mussel mucin-hyaluronic acid nanogel can be swelled in a water-based medium to form a three-dimensional space net-shaped structure, pharmaceutical active molecules are better entrapped, lysine and dopa groups in the structure can be tightly combined with the surface or mucous membrane of an organism through electrostatic interaction, hydrogen-bond interaction and oxidative crosslinking, so that the bioavailability of the mussel mucin-hyaluronic acid nanogel is improved, and the bioavailability of the mussel mucin-hyaluronic acid nanogel is improved. The carrier has good biological adhesion, can prolong the residence time of the carrier on an organism or mucous membrane surface, and promotes drug absorption. The mussel mucin-hyaluronic acid nanogel can also be used as a drug storage cavern, so that the slow release effect of drugs is improved, the action time of the drugs is prolonged, and the administration frequency is reduced.

The invention discloses a preparation method of high-purity recombinant mussel mucoprotein, and belongs to the technical field of recombinant protein preparation, the idea of improving target protein expression by adopting fusion protein is adopted, and fusion expression is performed on partial peptide fragments of an amino acid sequence of mytilus coruscus Mfp-3 and an amino acid sequence of common mussel preCol-D to obtain the high-purity recombinant mussel mucoprotein. The recombinant mussel mucin which is high in purity, low in endotoxin content and good in adhesion performance is obtained by combining improvement of induction, tyrosinase modification and separation and purification processes, a new thought is provided for industrial production of the recombinant mussel mucin through successful preparation of the recombinant mussel mucin, raw material support is provided for multi-field application of the recombinant mussel mucin, and the method is suitable for industrial production of the recombinant mussel mucin. The customized sequence recombinant mussel mucoprotein is prepared according to application requirements, and the application of the mussel mucoprotein in different fields is promoted.

The invention relates to the technical field of hydrogel, in particular to mussel mucoprotein loaded extracellular vesicle hydrogel as well as a preparation method and application thereof. The hydrogel is prepared by adopting a mode of combining human umbilical cord mesenchymal stem cell exosome Exo and mussel mucoprotein MAP; the method has the following advantages: 1, the wound repair effect is improved: the biological activity of the exosome Exo and the adhesion performance of the mussel mucin MAP are utilized to jointly promote the wound repair process, so that the repair effect is improved; 2, the adhesion performance is enhanced: the strong adhesion of the mussel adhesive protein MAP is utilized to ensure that the hydrogel can be tightly attached to the wound surface in a wet environment, and the dressing is prevented from falling off and infection risk; and 3, multifunctionality is realized: the composite hydrogel not only has the basic functions of promoting healing, resisting bacteria and the like, but also can transmit genetic information through exosome Exo, so that tissue regeneration and skin barrier repair are further promoted.

The invention is suitable for the technical field of gynecological gels, and provides a gynecological gel with a repairing effect. Comprising the following components in percentage by weight: 0.1%-0.5% of recombinant III type human collagen, 0.05%-0.2% of mussel mucin, 1%-3% of chitosan, 0.2%-1% of sodium hyaluronate, 2%-5% of lactobacillus fermentation product filtrate, 0.05%-0.2% of tea tree essential oil, 0.2%-0.5% of carbomer, 0.1%-0.4% of triethanolamine, 0.1%-0.2% of sodium methylparaben and the balance of purified water. The gynecological gel with the repairing effect has the excellent repairing effect, integrates multiple effects of effectively resisting bacteria and diminishing inflammation, promoting repairing of damaged vaginal mucosa, adjusting vaginal micro-ecological balance and the like, not only can efficiently inhibit growth of various pathogens, but also can remarkably promote proliferation and repairing of vaginal mucosa cells, and has the advantages that the repairing effect is good, and the repairing effect is good. The vaginal micro-ecological balance can be accurately adjusted, no stimulation is caused to vaginal mucosa, safety and reliability are achieved, and long-term use can be achieved.

The invention provides application of G3BP1 in preparation of a medicine for protecting barrier function integrity of vascular endothelial cells, and belongs to the technical field of biological medicine manufacturing. The invention provides application of G3BP1 in preparation of a medicine for protecting barrier function integrity of vascular endothelial cells. The present invention relates to G3BP1 that ensures the sustained expression of key adherent junction proteins (VE-cadherin, p120) by directly binding to and stabilizing the mRNA of these proteins; meanwhile, the G3BP1 is combined with the MYD88mRNA to promote the degradation of the MYD88mRNA, so that a permeability-promoting MYD88-ARNO-ARF6 signal channel is inhibited, especially under the condition of an inflammation period. Therefore, the G3BP1 regulates and maintains the integrity of the vascular barrier through double transcription, and a new treatment strategy is provided for damage repair of the functional integrity of the vascular endothelial cell barrier.

The invention relates to a Raman probe for detecting hydrogen sulfide as well as a preparation method and application of the Raman probe. The gold and silver nanocage (AuAg NCs) is prepared, and after the gold and silver nanocage (AuAg NCs) is modified by a Raman signal molecule 4-ethynylaniline (4EA), it is found that the AuAg-4EANCs shows the strongest Raman enhancement effect at the position of 2010 cm <-1 > located in a cell silence zone. The SERS probe with the tumor targeting capability is developed through the functional modification of a mucoprotein 1 aptamer (MUin1aptamer, MUC1Apt) and polyethylene glycol (PEG), and the SERS probe with the tumor targeting capability is further developed through the functional modification of the mucoprotein 1 aptamer (MUin1aptamer, MUC1Apt) and the PEG (Polyethylene Glycol). In the presence of hydrogen sulfide (H2S) and oxygen, Ag in AuAg-4EANCs rapidly reacts with H2S to generate Ag2S with significantly reduced Raman enhancement performance, resulting in sharp attenuation of 4EA signal intensity. And along with the increase of the H2S concentration, the generation amount of Ag2S is increased, so that a quantitative detection model dependent on the H2S concentration is established.

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The invention discloses a preparation method of recombinant mussel mucin rich in dopa, and belongs to the technical field of genetic engineering. When the recombinant mussel mucoprotein is co-expressed and modified, a certain amount of modifier is fed in the induction process according to the growth of thalli and the expression condition of protein, so that on one hand, the component concentration of a co-expression modification system is controlled, and a favorable environment is provided for the recombinant tyrosinase to oxidize tyrosine into DOPA; on the other hand, an environment is created for the synthesized recombinant mussel mucin containing dopa, the situation that dopa residues are oxidized into unnecessary substances such as dopaquinone and melanin due to long co-expression modification time is avoided, glutamic acid with a certain concentration in a modification auxiliary system serves as energy supply to promote modification, and the dopa oxidation rate and modification efficiency are improved.

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and / or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and / or light chain regions of the antibodies, or antigen-binding portions thereof.

The application discloses a preparation method of high-purity recombinant mussel adhesive protein and belongs to the technical field of recombinant protein preparation. The amino acid sequence of Mfp-3 of Mytilus coruscus and the partial peptide segment of the amino acid sequence of preCol-D of Mytilus edulis are fused and expressed according to the idea of improving target protein expression by using fusion protein, and the improvement of the induction, tyrosinase modification and separation and purification process is combined to obtain the recombinant mussel adhesive protein with high purity, low endotoxin content and good adhesion performance. The successful preparation of the recombinant mussel adhesive protein provides a new idea for the industrial production of the recombinant mussel adhesive protein, provides raw material support for the multi-field application of the recombinant mussel adhesive protein, realizes the preparation of the customized sequence recombinant mussel adhesive protein according to application requirements, and promotes the application of the mussel adhesive protein in different fields.

To provide a technique for reducing the count of bacteria involved in mucin decomposition within the intestine, wherein the present invention allows inhibition of growth of intestinal microbes such as Ruminococcus gnavus, which can be involved in mucin degradation; and thus, it becomes possible to reduce mucin degradation within the intestine, thereby preserving the intestinal barrier function, and contributing to the maintenance or enhancement of host health.SOLUTION: Provided is an agent that comprises agaro-oligosaccharides as an active ingredient to inhibit the growth of intestinal bacteria having, in genomic DNA, a NanA gene composed of a DNA sequence having at least 45.6% sequence identity to Sequence No. 1 (NanA gene of Ruminococcus gnavus).SELECTED DRAWING: Figure 1

The present invention relates to Akkermansia muciniphila Akk11 having the functions of regulating blood glucose and blood fat and the use thereof. Said Akkermansia muciniphila Akk11 is classified and named as Akkermansia muciniphila Akk11 with the accession number of CCTCC NO: M2024119. The strain uses mucin as the unique source of carbon element and nitrogen element, so as to control the basic regulatory systems of glucose and energy metabolism, protect the integrity of intestinal epithelial cells and mucus layers to exert a protective effect on metabolism, regulate the levels of blood glucose and blood fat, and remarkably relieve symptoms of metabolic disorders, and thus providing strategies and reference basis for the prevention and treatment of obesity.

The invention relates to the technical field of gynecological gel, and discloses gynecological gel containing recombinant mussel mucin as well as a preparation method and application of the gynecological gel. The gynecological gel containing the recombinant mussel mucin comprises the following raw material components in percentage by mass: 0.01%-50% of the recombinant mussel mucin, 0.1%-20% of a gel matrix, 0.01%-1.0% of a pH regulator, 0.05%-1% of a preservative, 0.5%-20% of a humectant, 10%-50% of a protein protective agent and the balance of water, the gel matrix comprises a thickening agent and a suspending aid, and the protein protective agent is obtained by dissolving a dispersing agent, a chelating agent and a protein stabilizer in a buffer solution. The gynecological gel provided by the invention has good film-forming property, forms a protective gel film on a vaginal wall, physically isolates the vaginal wall from external bacteria, is used for protecting gynecological mucosa and preventing colonization of pathogenic microorganisms, has good anti-inflammatory and anti-oxidation effects, and can be used for preventing or treating gynecological diseases.

The invention relates to Ackermania muciniphila and application thereof, and belongs to the technical field of microorganisms. According to the present invention, the ackermania muciniphilaSYSU-85 is adopted as the ackermania muciniphilaSYSU-85, and has been preserved in the China General Microbiological Culture Collection Center (CGMCC) on August 8, 2024, and the preservation number of the ackermania muciniphilaSYSU-85 is CGMCC NO.46070; the Ackermania muciniphila SYSU-85 disclosed by the invention is weak in dependence on mucin, grows well in a BHI culture medium added with cysteine, and is resistant to oxaliplatin. The Ackermansiella muciniphila SYSU-85 provided by the invention alleviates adverse reactions caused by oxaliplatin, and is combined with oxaliplatin or a PD-1 inhibitor to significantly slow down a tumor growth curve and significantly reduce the tumor volume, thereby improving the tumor treatment effect.

The invention relates to the technical field of medical dressings, and discloses a scar repair gel containing recombinant mussel mucin and a preparation method thereof. The scar repair gel is prepared from the following components in percentage by mass: 0.01 to 0.2 percent of recombinant mussel mucin, 0.4 to 0.8 percent of a thickening agent, 6 to 15 percent of a compound emulsifier, 1 to 2 percent of a pH regulator, 20 to 40 percent of silicone, 0.1 to 0.3 percent of a preservative and the balance of water, wherein the silicone comprises polydimethylsiloxane, a polydimethylsiloxane cross-linking agent and decamethylcyclopentasiloxane. The scar repair gel containing the recombinant mussel mucin has good film-forming property, forms a moisturizing barrier on the surface of a wound, can inhibit formation of hyperplasia scars, reduces pruritus in the wound healing process, reduces generation and deposition of melanin, and has the effects of repairing scars and repairing scars. The comfort of a patient in the use process and the compounding stability of the mussel mucin and silicone gel system are effectively improved.

Disclosed herein are double stranded ribonucleic acids (dsRNAs) and synthetic antisense oligonucleotides (ASOs) for use in inhibiting the expression of MUC5B and in the treatment of a subject having a disease or disorder characterized by overexpression of MUC5B, including in subjects having lung disease or in a subject at risk of developing lung disease, for example, in a subject having or at risk of developing idiopathic pulmonary fibrosis.

The invention relates to the technical field of medical dressings, and discloses a compound hydrogel dressing based on recombinant mussel mucin and a preparation method of the compound hydrogel dressing. The compound hydrogel based on the recombinant mussel mucin is prepared from the following raw material components in parts by weight: 0.01 to 0.3 part of the recombinant mussel mucin, 0.1 to 2.0 parts of a thickening agent, 10 to 21 parts of a polysaccharide composition, 1 to 8 parts of a humectant, 0.01 to 0.5 part of a pH (Potential of Hydrogen) regulator, 0.05 to 0.2 part of a preservative, 0.05 to 0.2 part of a metal ion chelating agent and 68 to 88 parts of purified water, the polysaccharide composition is prepared from glucan, chitosan and hyaluronic acid. The polysaccharide is compounded into the hydrogel of the recombinant mussel mucoprotein to play a role synergistically, and the polysaccharide and the recombinant mussel mucoprotein are closely combined and cross-linked, so that the adhesion of the compound hydrogel dressing is effectively improved, wound healing is promoted, the anti-inflammatory effect is improved, and meanwhile, a good protective barrier environment is formed for wound repair and healing.

The application provides a mussel mucin synthesis method and relates to the technical field of genetic engineering.The application improves the yield of mussel mucin by carrying out deletion mutation on the N-terminal sequence of the secondary structure of the mussel mucin amino acid sequence such as SEQ ID NO.1.The yield of mussel mucin in the prior art is about 2.57g / L, while the yield of mussel mucin in the application is about 5g / L, which is greatly improved compared with the yield of mussel mucin in the prior art.On this basis, the mussel mucin is modified by dopa through co-expression of tyrosinase, and the expression amount of the tyrosinase is controlled through different intensities of RBS, so as to regulate the modification degree of dopa, improve the yield of mussel mucin, and realize controllable modification of dopa in the mussel mucin, finally obtaining mussel mucin with high yield and different modification degrees of dopa.

The present invention relates to modified recombinant agrin proteins or fragments thereof and recombinant chimeric laminin-nidogen proteins or fragments thereof, nucleic acid sequences encoding these proteins, vectors containing these nucleic acid sequences, compositions comprising these proteins, and the use of these proteins in the prevention and / or treatment of congenital muscular dystrophies, in particular (laminin-α2) LAMA2-associated muscular dystrophy.

The invention relates to the technical field of biology, in particular to a double-layer microcapsule of ackermania mucilaginosa and prebiotics and a preparation method thereof.The double-layer microcapsule is prepared from bacteria and mixed gum, the weight ratio of the bacteria to the mixed gum is 1: 5, the bacteria are ackermania mucilaginosa, and the mixed gum comprises sodium alginate, carob gum or xanthan gum; the embedding rate of the microcapsule is 91.00%-96.14%, the survival rate is obviously improved, and the protection capability on strains is improved; under the three storage temperatures, the survival rate of the microcapsule embedded bacterial strain added with the prebiotics is obviously higher than that of the microcapsule without the prebiotics under the same condition.

The invention belongs to the technical field of biological detection, and discloses a sequence combination for rapidly detecting influenza A based on CRISPR / CAS12a-MIRA and application, the sequence combination comprises an MIRA primer pair (SEQ ID NO: 1-2) of a targeted influenza A virus M gene highly conserved region (M1 fragment), and CRISPR / Cas12a detection probes (crRNA SEQ ID NO: 3 and phosphorothioate modified FAM-biotin probe SEQ ID NO: 4). By optimizing a buffer system (containing PEG 8000 and betaine), MIRA amplification and CRISPR detection are continuously completed in a closed tube at 37-42 DEG C, and a result is output within 30 minutes. The detection sensitivity of the kit reaches 50 copies / [mu] L, the specificity is 100%, and subtypes such as H1N1, H3N2, H5N1 and H7N9 can be covered. Compared with the prior art, according to the scheme, the detection time is shortened by 67%, the probe cost is reduced by 80%, and high anti-interference performance (tolerance to 10% mucoprotein and 5% whole blood) is achieved. The kit is suitable for on-site instant detection of saliva, nasopharynx swabs and environmental samples, and an efficient and portable solution is provided for basic medical institutions and prevention and control of sudden epidemic situations.

The present invention relates to the field of biotechnology, and in particular to an oral stem cell factor preparation and a preparation method thereof. The preparation method of the oral stem cell factor preparation comprises the following steps: (1) adding mussel mucin to a stem cell factor concentrate and mixing evenly; (2) adding synephrine to the mixture of step (1), and freeze-drying to obtain the product. The present invention innovatively adds mussel mucin and synephrine components to the stem cell factor concentrate. Among them, the synergistic effect of mussel mucin and synephrine can effectively maintain the activity of stem cell factor. The preparation method provided by the present invention has simple steps, and the obtained oral stem cell factor preparation can not only improve insulin secretion, but also has anti-inflammatory effect.

The application discloses a plant lactobacillus strain and application thereof, and belongs to the technical field of microorganisms. The preservation number of the strain is CGMCC No. 33864. The strain has good tolerance to gastrointestinal juice and bile salts and has no hemolytic activity. Concentrated cell-free supernatant prepared from the strain can inhibit salmonella, including inhibiting the growth of salmonella, killing bacteria, inhibiting or removing biofilm. Animal experiments show that the strain and the concentrated cell-free supernatant thereof can prevent salmonella infection, alleviate weight loss caused by infection, maintain intestinal barrier integrity, reduce the level of pro-inflammatory factors, alleviate tissue damage, improve the expression of colon tight junction proteins and mucin, promote the generation of short-chain fatty acids, and restore the intestinal flora structure. The application further provides a microbial preparation containing the strain and / or the concentrated cell-free supernatant thereof. The strain and the microbial preparation can be used for preparing products for resisting salmonella, preventing salmonella infection or improving intestinal health.

The invention relates to the technical field of biological medicine, in particular to mussel mucin and hyaluronic acid cross-linked self-repairing eye health care cream and a 4D forming method thereof. The composition comprises stearic acid, cetostearyl alcohol and the like, a lactic acid bacteria fermentation extract, a jasmine flower extract, a wolfberry extract, a pseudo-ginseng extract, a cassia seed extract, a polygonum cuspidatum extract, a chrysanthemum extract, a leontopodium leontopodum extract, ethylparaben, methylparaben and the like, decapeptide-4, mussel mucin, proteoglycan protein and modified graphene. Modified graphene in the self-repairing eye health care cream can effectively promote crosslinking of mussel mucin and hyaluronic acid and improve the repairing effect, the micro-current effect of graphene can also promote skin tissue to absorb traditional Chinese medicine components and deeply repair eyes, the effect can be more obvious according to personal eye conditions and requirements, and the self-repairing eye health care cream has a good application prospect. The composition has the effects of relieving asthenopia, dryness and soreness, effectively delaying excessive growth of an ocular axis, relieving temporary myopia drift, relieving asthenopia and protecting near vision.

The invention provides a fusion protein with high repair capacity, a preparation method and application thereof, and belongs to the technical field of hybrid peptides. The amino acid sequence of the fusion protein is shown as SEQ ID NO.1; the fusion protein is obtained by sequentially connecting the following modules in series: a functional domain 1 of fibronectin, a hydrophilic region 1 of elastin, a functional domain 1 of mussel mucin, a hydrophilic region 2 of elastin, a functional domain 2 of fibronectin, a hydrophilic region 3 of elastin, a functional domain 2 of mussel mucin, a hydrophilic region 4 of elastin and an integrin binding region of elastin. The fusion protein of fibronectin, elastin and mussel mucin is constructed, and the nucleotide sequence of the fusion protein is optimized, so that the relative migration rate of keratinocytes can be obviously improved, the expression quantity of repair-related genes of HaCat cells can be improved, the secretion quantity of skin stimulating factors can be reduced, and the inhibition rate on hyaluronidase can be improved; the skin repairing and relieving capability is improved.

The invention relates to the field of cell culture and discloses a culture medium for thick-shelled mussel mantle cells and an application thereof. The culture medium comprises a basal culture medium and additives, wherein the additives comprise thick-shelled mussel serum, proanthocyanidins, bovine insulin, growth factors, antibiotics, defensins, mussel mucin and a buffer. The culture medium can be used for in vitro culture of thick-shelled mussel mantle cells and can better maintain the survival and growth of in vitro cultured thick-shelled mussel mantle cells. Defensins in a specific proportion are added to the culture medium, and the best growth and reproduction state can be achieved when the thick-shelled mussel mantle cells are cultured using the culture medium in the specific proportion. The application also provides an application method of the culture medium, which is simple to operate and can produce cultured thick-shelled mussel mantle cells with high cell density, good morphology and high wall adhesion.